Generic company IPR study reveals “surprisingly high” institution rate
A Foley & Lardner study of generic drug company IPRs against pharmaceutical patents shows an increased willingness to use the PTAB, an above-average institution rate but below-average invalidation rate
Generic drug companies filing inter partes review (IPR)
petitions at the Patent Trial and Appeal Board (PTAB) have a
"surprisingly high" institution rate but a lower invalidation
rate in final decisions, according to a
study by Foley & Lardner.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.